Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from CEPI

Africa CDC Moves to Test Merck's Licensed Ebola Vaccine Against Bundibugyo as Congo Outbreak Becomes Country's Largest

Africa CDC plans to ask WHO advisers to allow testing of Ervebo against Bundibugyo Ebola. No trial is approved, and no protection is proven.

Medical Daily

The First Vaccine Built for This Ebola Strain Has Entered Human Testing as the DRC Outbreak Becomes the Country's Largest

Oxford launched the first Phase 1 trial of a Bundibugyo Ebola vaccine. Licensed Ebola vaccines target a different species and do not cover this strain.

Medical Daily

Merck-Backed Lab Gets $8.5 Million to Fast-Track a Vaccine for a Rapidly Spreading Ebola Outbreak

Hilleman Laboratories, a Singapore-based joint venture of Merck & Co. Inc. (NYSE:MRK) MSD division and Wellcome, said Thursday it will develop and manufacture clinical trial doses of an investigational Bundibugyo Ebola vaccine with up to $8.5 million in funding from the Coalition for Epidemic Preparedness Innovations (CEPI).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

The Ebola Strain Spreading Right Now Has No Vaccine — And the U.S. Just Committed $270 Million to Fight It

Bundibugyo Ebola has no approved vaccine or treatment. 676 cases, 136 deaths. U.S. airports screen arrivals as $270M response mobilizes.

Medical Daily

3 new Ebola vaccines are being fast-tracked amid the current outbreak — when could they be ready?

The Bundibugyo virus driving the current Ebola outbreak has no approved vaccine, but researchers are leveraging decades of vaccine innovation in an effort to change that.

LiveScience

Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI funding

Serum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fresh funding to combat a spreading outbreak in Africa. The vaccine uses technology similar to the Oxford-AstraZeneca Covid-19 vaccine. This partnership aims to accelerate development and ensure access…

The Economic Times

Moderna and other groups get $60 million to develop Ebola vaccine

CEPI is investing around $60 million to speed up the creation of vaccines against the deadly Ebola Bundibugyo virus. This funding will support Moderna, the University of Oxford, and the International AIDS Vaccine Initiative. The goal is to have trial-ready vaccines within months.

The Economic Times

Read news from The Economist, FT, and more,
with one subscription

Global health funders fast-track three Ebola vaccines as outbreak continues to spread in Africa

Global health body CEPI is fast-tracking three experimental vaccines against the Bundibugyo strain of Ebola as the outbreak in Central Africa continues to spread.

Euronews

Ebola case confirmed in rebel-held area of DR Congo

A rebel-held area of the Democratic Republic of Congo - hundreds of kilometres from an Ebola outbreak's epicentre - has recorded a fatal case of ‌the disease.

AAP

Future pandemics are a 'certainty' — and we must be better prepared to distribute vaccines equitably, says Dr. Seth Berkley

Months before COVID-19 was declared a pandemic, efforts were already underway to ensure low-income countries would get access to future vaccines against the infection. The book "Fair Doses" tells that story and discusses the ongoing fight for vaccine equity around the world.

LiveScience

One of science’s greatest achievements: how the rapid development of COVID vaccines prepares us for future pandemics

Since COVID was first reported in December 2019, there have been more than 775 million recorded infections and more than 7 million deaths from the disease. This makes COVID the seventh-deadliest pandemic in recorded history.

The Conversation

Scientists test world-first Nipah virus vaccine

It uses the same vaccine technology as the Oxford Covid jab.

The Independent UK

Disease X vaccine ‘could be ready within 100 days of new threat emerging’

Researchers will also seek ways to speed up manufacture of jabs so vaccines could be rolled out more quickly in the event of a future outbreak.

The Independent UK

Fast-tracking a Lassa fever vaccine

The Covid-19 pandemic may have exposed the vulnerability of the world's health systems, but it also led to a truly impressive achievement: The development and production of life-saving vaccines more quickly than ever before.

Bangkok Post

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

‘A silver lining’: how Covid ushered in a vaccines golden era

Pandemic accelerated advances in vaccine technology, opening up possibilities for combating array of diseases

ABC News

Cancelled University of Queensland COVID-19 vaccine to be trialled in humans next year

The University of Queensland's vaccine had to be abandoned during the rush to develop an effective COVID-19 shot, but now will be trialled on people.

Al Jazeera

British agencies secure funds to develop standard monkeypox tools

CEPI allocated $375,000 just a few days after the WHO declared the disease a global health emergency.

The Hindu

CBI to probe “irregularities” in leasing out enemy assets

Four separate cases registered; searches carried out at 40 locations

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

Hopes for 'variant-proof' COVID-19 vaccine

Sydney University is hoping to develop a COVID-19 vaccine that will protect against all known variants of concern, as well as future strains of the virus.

The Hindu

Consortium with Bharat Biotech to get $19.3 mn. for ‘futuristic’ jab

Funding is to support development of a ‘variant-proof’ vaccine candidate

Benzinga

The Daily Biotech Pulse: Pfizer Goes Shopping, AstraZeneca Inks Bispecific Antibody Deal, Aptinyx Faces Clinical Study Setback, Erytech Jumps On Data And More

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Vaxxinity Receives $9.25M Funding From CEPI To Support Pivotal COVID-19 Vaccine Trial

The Coalition for Epidemic Preparedness Innovations (CEPI) and Vaxxinity Inc (NASDAQ:VAXX) will co-fund the ongoing global Phase 3 trial of Vaxxinity's next-generation UB-612 COVID-19 vaccine candidate. The candidate is under development as a heterologous – or 'mix-and-match' – booster dose. CEPI will provide up to $9.25 million in funding. The Phase 3 trial, which began in…

The Independent UK

Rich countries getting new COVID vaccine before poorer ones

The company behind a COVID-19 vaccine touted as a key tool for the developing world will miss a target for giving doses to the U.N.-backed effort to deliver shots to poorer countries

Daily Mirror

New 'variant proof' Cambridge University Covid jab receives backing worth millions

The new "variant proof" coronavirus vaccine by Cambridge University has received global backing worth up to £32million with PM Boris Johnson commending the project

Benzinga

Moderna Plans Vaccines Against 15 Pathogens With Future Pandemic Potential

Moderna Inc (NASDAQ: MRNA) plans to develop and begin testing vaccines targeting 15 pathogens identified as the biggest public health risk by WHO and CEPI by 2025. The Company also said it would permanently wave its COVID-19 vaccine patents for shots intended for certain low- and middle-income countries. At its global public health strategy,…

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the University of Oxford

185 stories

University of Sydney

184 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Democratic Republic of Congo

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.